Septerna (SEPN)
Market Price (5/14/2026): $24.76 | Market Cap: $1.1 BilSector: Health Care | Industry: Biotechnology
Septerna (SEPN)
Market Price (5/14/2026): $24.76Market Cap: $1.1 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -29% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 7296% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 149%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 148% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -43% Attractive yieldFCF Yield is 9.7% Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Biopharmaceutical R&D, and Targeted Therapies. | Weak multi-year price returns2Y Excs Rtn is -28%, 3Y Excs Rtn is -64% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -68 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -94% Stock price has recently run up significantly12M Rtn12 month market price return is 268% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 18% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -7.5% Key risksSEPN key risks include [1] the recent clinical trial failure and discontinuation of its lead asset, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -29% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 7296% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 149%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 148% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -43% |
| Attractive yieldFCF Yield is 9.7% |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Biopharmaceutical R&D, and Targeted Therapies. |
| Weak multi-year price returns2Y Excs Rtn is -28%, 3Y Excs Rtn is -64% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -68 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -94% |
| Stock price has recently run up significantly12M Rtn12 month market price return is 268% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 18% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -7.5% |
| Key risksSEPN key risks include [1] the recent clinical trial failure and discontinuation of its lead asset, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Septerna reported significantly improved financial results for the first quarter of 2026, exceeding analyst expectations for both revenue and earnings per share. The company's revenue reached $26.5 million, a substantial increase from $0.2 million in the prior-year period, primarily driven by its collaboration with Novo Nordisk. This figure significantly surpassed the analyst consensus estimate of $16.94 million. Concurrently, Septerna narrowed its net loss to $8.6 million, or -$0.19 per share, outperforming the estimated loss of -$0.42 per share.
2. The company announced positive advancements in its clinical pipeline with key programs progressing. In March 2026, Septerna presented positive Phase 1 clinical trial data for SEP-631, an oral small molecule for mast cell-driven diseases, which supports its advancement into Phase 2b development for chronic spontaneous urticaria (CSU) in the second half of 2026. Additionally, in April 2026, Septerna initiated a Phase 1 clinical trial for SEP-479, an oral small molecule for hypoparathyroidism, with data anticipated in late 2026 or early 2027.
Show more
Stock Movement Drivers
Fundamental Drivers
The 6.0% change in SEPN stock from 1/31/2026 to 5/13/2026 was primarily driven by a 227.8% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312026 | 5132026 | Change |
|---|---|---|---|
| Stock Price ($) | 23.34 | 24.75 | 6.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 22 | 72 | 227.8% |
| P/S Multiple | 46.9 | 15.3 | -67.3% |
| Shares Outstanding (Mil) | 44 | 45 | -0.9% |
| Cumulative Contribution | 6.0% |
Market Drivers
1/31/2026 to 5/13/2026| Return | Correlation | |
|---|---|---|
| SEPN | 6.0% | |
| Market (SPY) | 7.6% | 25.6% |
| Sector (XLV) | -4.8% | 24.7% |
Fundamental Drivers
The 20.1% change in SEPN stock from 10/31/2025 to 5/13/2026 was primarily driven by a 9852.5% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 10312025 | 5132026 | Change |
|---|---|---|---|
| Stock Price ($) | 20.60 | 24.75 | 20.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 72 | 9852.5% |
| P/S Multiple | 1,253.2 | 15.3 | -98.8% |
| Shares Outstanding (Mil) | 44 | 45 | -1.3% |
| Cumulative Contribution | 20.1% |
Market Drivers
10/31/2025 to 5/13/2026| Return | Correlation | |
|---|---|---|
| SEPN | 20.1% | |
| Market (SPY) | 9.5% | 19.6% |
| Sector (XLV) | 2.6% | 23.0% |
Fundamental Drivers
The 255.6% change in SEPN stock from 4/30/2025 to 5/13/2026 was primarily driven by a 6621.4% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302025 | 5132026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.96 | 24.75 | 255.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 72 | 6621.4% |
| P/S Multiple | 287.6 | 15.3 | -94.7% |
| Shares Outstanding (Mil) | 44 | 45 | -0.8% |
| Cumulative Contribution | 255.6% |
Market Drivers
4/30/2025 to 5/13/2026| Return | Correlation | |
|---|---|---|
| SEPN | 255.6% | |
| Market (SPY) | 35.4% | 20.5% |
| Sector (XLV) | 6.3% | 9.9% |
Fundamental Drivers
nullnull
Market Drivers
4/30/2023 to 5/13/2026| Return | Correlation | |
|---|---|---|
| SEPN | ||
| Market (SPY) | 85.5% | 23.9% |
| Sector (XLV) | 15.5% | 13.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SEPN Return | - | - | - | 7% | 22% | -11% | 16% |
| Peers Return | 36% | 28% | 58% | 34% | 11% | -8% | 274% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 97% |
Monthly Win Rates [3] | |||||||
| SEPN Win Rate | - | - | - | 67% | 58% | 40% | |
| Peers Win Rate | 55% | 55% | 58% | 55% | 45% | 44% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| SEPN Max Drawdown | - | - | - | -6% | -78% | -17% | |
| Peers Max Drawdown | -9% | -26% | -14% | -7% | -30% | -17% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: CRNX, LLY, VKTX, REGN, AMGN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/13/2026 (YTD)
How Low Can It Go
In The Past
Septerna's stock fell -9.5% during the 2025 US Tariff Shock. Such a loss loss requires a 10.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
In The Past
Septerna's stock fell -9.5% during the 2025 US Tariff Shock. Such a loss loss requires a 10.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Septerna (SEPN)
AI Analysis | Feedback
Here are a few analogies to describe Septerna:
Moderna for GPCR drug discovery
CRISPR Therapeutics for GPCRs
AI Analysis | Feedback
- Oral small molecule drug candidates for endocrinology: These are novel GPCR-targeted therapies in Septerna's pipeline aimed at treating endocrine diseases.
- Oral small molecule drug candidates for immunology and inflammation: These are novel GPCR-targeted therapies in Septerna's pipeline aimed at treating immune and inflammatory conditions.
- Oral small molecule drug candidates for metabolic diseases: These are novel GPCR-targeted therapies in Septerna's pipeline aimed at treating metabolic disorders.
AI Analysis | Feedback
Septerna (SEPN) is a clinical-stage biotechnology company focused on the discovery and development of oral small molecule drugs targeting G protein-coupled receptors (GPCRs). As such, its ultimate customers are not other companies, but individual patients who will be prescribed these medications once they are developed, approved, and commercialized.
The categories of customers (patients) that Septerna aims to serve are primarily those suffering from diseases within its initial three therapeutic areas:
- Patients with endocrinology-related diseases.
- Patients with immunology and inflammation-related diseases.
- Patients with metabolic diseases.
AI Analysis | Feedback
nullAI Analysis | Feedback
Jeffrey Finer, Chief Executive Officer & Co-Founder
Jeffrey Finer was appointed CEO of Septerna in November 2021 and is also a co-founder of the company. He has a background in founding and launching multiple new biotechnology companies, including Maze Therapeutics and Ambys Medicines. Dr. Finer has held R&D leadership positions at Theravance Biopharma, Five Prime Therapeutics, and Cytokinetics. He also serves as a Venture Partner at Third Rock Ventures, which led Septerna's Series A financing and retained a minority stake after the company's IPO, indicating a pattern of managing companies backed by private equity firms.
Gil Labrucherie, Chief Financial Officer
Gil Labrucherie was appointed Chief Financial Officer of Septerna effective January 6, 2025. He brings over 25 years of senior leadership experience in finance and legal roles within public biopharmaceutical and technology companies. Prior to Septerna, Mr. Labrucherie served as CFO and Chief Business Officer at ACELYRIN, and as CFO, COO, and SVP/General Counsel at Nektar Therapeutics. He has a track record of raising over $1.5 billion in private and public equity capital and generating over $1 billion in realized value from strategic partnering transactions. Earlier in his career, he held executive leadership positions at various high-growth technology companies. He currently serves on the board of Rezolute, Inc.
Liz Bhatt, President and Chief Operating Officer
Liz Bhatt joined Septerna as Chief Operating Officer in July 2022 and brings over 25 years of experience in strategy, deal-making, and company-building across biotech and pharmaceutical companies. Her previous roles include Chief Business & Strategy Officer at Applied Molecular Transport (AMT) and Chief Operating Officer at Achaogen. Ms. Bhatt also spent over a decade at Gilead Sciences, holding positions as VP, Corporate Development and Senior Director, Commercial Strategy.
Daniel Long, Senior Vice President, Drug Discovery
Daniel Long serves as the Senior Vice President of Drug Discovery at Septerna.
Jae Kim, Chief Medical Officer
Jae Kim holds the position of Chief Medical Officer at Septerna.
AI Analysis | Feedback
The key risks for Septerna (SEPN) are primarily associated with the inherent challenges of drug development in the biotechnology sector and the reliance on its proprietary technology.
- Clinical Development and Regulatory Approval Risk: As a clinical-stage biotechnology company, Septerna's success is entirely contingent upon the successful development, clinical trial completion, and regulatory approval of its product candidates. Drug development is a lengthy, costly, and highly uncertain process with a high rate of failure at every stage, from preclinical studies to post-marketing. The company currently has a deep pipeline of product candidates, but none have yet reached commercialization, meaning there is no current revenue from drug sales. Failure to achieve favorable results in clinical trials or obtain necessary regulatory approvals would significantly impair or prevent the commercialization of its product candidates and, consequently, its ability to generate revenue.
- Platform Technology Risk: Septerna's entire drug discovery and development strategy is powered by its proprietary Native Complex Platform™. The company asserts that this platform uniquely replicates the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale, enabling the discovery of novel oral small molecule drug candidates. There is a risk that this platform may not consistently or effectively deliver viable drug candidates, or that its purported advantages over traditional drug discovery methods may not materialize as expected. If the platform proves less effective or less efficient than anticipated in identifying or optimizing drug candidates, Septerna's ability to build and advance its pipeline would be significantly hampered.
- Intellectual Property Risk: Septerna's business relies heavily on its proprietary Native Complex Platform™ and the intellectual property surrounding its drug candidates. The ability to protect its proprietary technology and future product candidates through patents, trade secrets, and other intellectual property rights is crucial for its competitive position. Challenges to the validity or enforceability of its existing or future patents, the inability to obtain new patent protection, or the unauthorized use or infringement of its intellectual property by third parties could significantly diminish its competitive advantage and its ability to monetize its discoveries.
AI Analysis | Feedback
nullAI Analysis | Feedback
Septerna (symbol: SEPN) is a clinical-stage biotechnology company focused on developing oral small molecule drugs for various therapeutic areas. The addressable markets for their main product candidates, based on their initial focus areas, are substantial on a global scale. The global addressable markets for Septerna's focus areas are: * The global endocrinology drug market is estimated to be valued at USD 77.44 billion in 2026 and is projected to reach USD 105.39 billion by 2033. * The global immunology & inflammatory diseases drugs market size reached US$ 212.76 billion in 2024 and is expected to reach US$ 431.11 billion by 2033. * The global metabolic disorder therapeutics market was valued at USD 103.85 billion in 2025 and is expected to increase to USD 167.86 billion by 2032.AI Analysis | Feedback
Septerna's (SEPN) future revenue growth over the next 2-3 years is expected to be driven by several key factors as the clinical-stage biotechnology company advances its pipeline and leverages strategic partnerships. The primary drivers of future revenue growth include: * Revenue from strategic collaborations and partnerships: A significant driver of Septerna's revenue comes from upfront payments, research services, and milestone payments associated with strategic alliances. The multi-billion-dollar collaboration with Novo Nordisk on oral incretin receptor agonists is a key example, having contributed a $195.0 million upfront payment in July 2025 and ongoing research service revenue. Additionally, the company received a $12.5 million milestone payment from Vertex in 2025, highlighting the continued potential for such payments as their pipeline progresses. * Advancement of lead pipeline candidate SEP-631 through clinical trials: Septerna is progressing SEP-631, an MRGPRX2 negative allosteric modulator for mast cell-driven diseases, including chronic spontaneous urticaria. Positive Phase 1 data for SEP-631 has been reported, and the company plans to initiate Phase 2b trials in the second half of 2026. Successful advancement through these later-stage trials is critical for generating further milestone payments from partners and ultimately for potential product commercialization. * Initiation and progression of other pipeline candidates, such as SEP-479: The company plans to initiate Phase 1 trials for SEP-479, a PTH1R agonist for hypoparathyroidism, in early 2026. Progress in these earlier-stage programs helps build value for the company and could lead to future licensing deals or collaborations. * Validation and expansion of the Native Complex Platform™ to foster new discovery programs: The positive Phase 1 results for SEP-631 validate Septerna's proprietary Native Complex Platform™. This validation demonstrates the platform's ability to discover new mechanisms of action and generate differentiated oral small molecules for challenging G protein-coupled receptors (GPCRs). The continued success and validation of this platform can attract new collaborations and expand Septerna's pipeline, creating additional future revenue opportunities.AI Analysis | Feedback
Share Repurchases
No information is available regarding share repurchases made by Septerna in the last 3-5 years. The reported "Buyback Yield" of -1,704.89% indicates share issuance rather than repurchases.
Share Issuance
- Septerna completed its upsized Initial Public Offering (IPO) on October 30, 2024, raising aggregate gross proceeds of $331.2 million by issuing 18,400,000 shares of common stock at $18.00 per share.
- The number of shares outstanding for Septerna increased by 1,704.89% in one year.
Inbound Investments
- In May 2025, Septerna announced a significant collaboration and license agreement with Novo Nordisk, valued at up to $2.2 billion, focused on developing oral medicines for obesity and other diseases.
- Revenue for Q4 2025 and the full year 2025 primarily reflected this collaboration work and the amortization of an upfront payment from Novo Nordisk.
Outbound Investments
No information is available regarding outbound investments made by Septerna in the last 3-5 years.
Capital Expenditures
- Capital expenditures for the full year 2025 were reported as $2.1 million.
- In the 12 months leading up to November 10, 2025, capital expenditures were -$1.07 million.
- These capital expenditures consumed a significant portion of the company's operating cash flow in 2025.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| With Septerna Stock Surging, Have You Considered The Downside? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to SEPN.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 186.97 |
| Mkt Cap | 39.4 |
| Rev LTM | 7,496 |
| Op Inc LTM | 1,887 |
| FCF LTM | 1,949 |
| FCF 3Y Avg | 1,734 |
| CFO LTM | 2,560 |
| CFO 3Y Avg | 4,568 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 47.4% |
| Rev Chg 3Y Avg | 25.2% |
| Rev Chg Q | 55.5% |
| QoQ Delta Rev Chg LTM | 10.8% |
| Op Inc Chg LTM | 11.4% |
| Op Inc Chg 3Y Avg | -6.3% |
| Op Mgn LTM | 25.8% |
| Op Mgn 3Y Avg | 26.3% |
| QoQ Delta Op Mgn LTM | 3.7% |
| CFO/Rev LTM | 28.9% |
| CFO/Rev 3Y Avg | 24.9% |
| FCF/Rev LTM | 23.1% |
| FCF/Rev 3Y Avg | 12.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 39.4 |
| P/S | 12.6 |
| P/Op Inc | 5.0 |
| P/EBIT | 3.6 |
| P/E | 4.6 |
| P/CFO | 12.6 |
| Total Yield | 0.1% |
| Dividend Yield | 0.2% |
| FCF Yield 3Y Avg | 0.2% |
| D/E | 0.0 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -3.3% |
| 3M Rtn | -6.8% |
| 6M Rtn | 0.8% |
| 12M Rtn | 27.2% |
| 3Y Rtn | 49.7% |
| 1M Excs Rtn | -11.3% |
| 3M Excs Rtn | -14.0% |
| 6M Excs Rtn | -3.5% |
| 12M Excs Rtn | -1.4% |
| 3Y Excs Rtn | -31.8% |
Price Behavior
| Market Price | $24.75 | |
| Market Cap ($ Bil) | 1.1 | |
| First Trading Date | 10/25/2024 | |
| Distance from 52W High | -19.8% | |
| 50 Days | 200 Days | |
| DMA Price | $24.99 | $18.73 |
| DMA Trend | up | down |
| Distance from DMA | -1.0% | 32.1% |
| 3M | 1YR | |
| Volatility | 59.3% | 79.5% |
| Downside Capture | 234.08 | 140.72 |
| Upside Capture | 146.36 | 256.11 |
| Correlation (SPY) | 22.8% | 18.7% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.53 | 0.99 | 1.13 | 1.03 | 1.36 | 0.07 |
| Up Beta | 0.39 | 0.45 | -0.22 | 0.98 | 0.20 | -1.22 |
| Down Beta | 0.14 | -2.12 | -1.52 | -0.52 | 0.12 | 0.27 |
| Up Capture | 146% | 131% | 273% | 193% | 695% | 56% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 13 | 21 | 33 | 60 | 128 | 183 |
| Down Capture | 870% | 245% | 207% | 138% | 146% | 98% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 9 | 21 | 30 | 64 | 120 | 188 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SEPN | |
|---|---|---|---|---|
| SEPN | 274.5% | 79.4% | 1.97 | - |
| Sector ETF (XLV) | 9.9% | 15.3% | 0.41 | 5.9% |
| Equity (SPY) | 28.9% | 12.0% | 1.82 | 17.9% |
| Gold (GLD) | 44.6% | 26.8% | 1.35 | -4.4% |
| Commodities (DBC) | 47.8% | 18.6% | 1.96 | -9.5% |
| Real Estate (VNQ) | 11.3% | 13.5% | 0.55 | 5.8% |
| Bitcoin (BTCUSD) | -21.3% | 41.7% | -0.46 | 2.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SEPN | |
|---|---|---|---|---|
| SEPN | 4.0% | 94.5% | 0.58 | - |
| Sector ETF (XLV) | 5.2% | 14.6% | 0.18 | 13.5% |
| Equity (SPY) | 13.7% | 17.1% | 0.63 | 23.7% |
| Gold (GLD) | 20.4% | 17.9% | 0.93 | -6.2% |
| Commodities (DBC) | 11.1% | 19.4% | 0.46 | -8.1% |
| Real Estate (VNQ) | 3.6% | 18.8% | 0.09 | 12.3% |
| Bitcoin (BTCUSD) | 7.5% | 55.9% | 0.35 | 9.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SEPN | |
|---|---|---|---|---|
| SEPN | 2.0% | 94.5% | 0.58 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.47 | 13.5% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 23.7% |
| Gold (GLD) | 13.4% | 15.9% | 0.70 | -6.2% |
| Commodities (DBC) | 8.3% | 17.9% | 0.38 | -8.1% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.22 | 12.3% |
| Bitcoin (BTCUSD) | 68.2% | 66.9% | 1.07 | 9.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/9/2026 | -3.6% | -13.5% | -15.7% |
| 11/10/2025 | -2.2% | 25.7% | 38.5% |
| 8/11/2025 | -2.5% | 0.9% | 28.1% |
| 3/27/2025 | 2.4% | -10.5% | 5.2% |
| 11/20/2024 | -3.2% | 10.1% | 7.9% |
| SUMMARY STATS | |||
| # Positive | 1 | 3 | 4 |
| # Negative | 4 | 2 | 1 |
| Median Positive | 2.4% | 10.1% | 18.0% |
| Median Negative | -2.8% | -12.0% | -15.7% |
| Max Positive | 2.4% | 25.7% | 38.5% |
| Max Negative | -3.6% | -13.5% | -15.7% |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Bhatt, Elizabeth | President and COO | Direct | Sell | 4172026 | 24.34 | 4,000 | 97,343 | 4,239,522 | Form |
| 2 | Shaikhly, Samira | Chief People Officer | Direct | Sell | 3042026 | 28.10 | 70,453 | 1,979,838 | 22,285 | Form |
| 3 | Bhatt, Elizabeth | President and COO | Direct | Sell | 2202026 | 28.97 | 4,000 | 115,860 | 5,045,975 | Form |
| 4 | Long, Daniel D | SVP, Drug Discovery | Direct | Sell | 11132025 | 18.06 | 3,501 | 63,223 | 1,677,843 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.